Analysts Set Assembly Biosciences Inc (NASDAQ:ASMB) Target Price at $53.67

Share on StockTwits

Shares of Assembly Biosciences Inc (NASDAQ:ASMB) have been assigned a consensus rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $53.67.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Chardan Capital reaffirmed a “hold” rating on shares of Assembly Biosciences in a research note on Sunday, June 30th. BidaskClub downgraded shares of Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research note on Monday, June 24th. Finally, William Blair reaffirmed an “outperform” rating on shares of Assembly Biosciences in a research note on Friday, May 10th.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers raised its holdings in Assembly Biosciences by 52.9% during the fourth quarter. Rhumbline Advisers now owns 27,744 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 9,602 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Assembly Biosciences by 15.3% during the fourth quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 3,100 shares in the last quarter. BlackRock Inc. raised its holdings in Assembly Biosciences by 3.4% during the fourth quarter. BlackRock Inc. now owns 1,909,510 shares of the biopharmaceutical company’s stock worth $43,193,000 after purchasing an additional 63,554 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Assembly Biosciences by 5.6% during the fourth quarter. Bank of New York Mellon Corp now owns 84,692 shares of the biopharmaceutical company’s stock worth $1,916,000 after purchasing an additional 4,459 shares in the last quarter. Finally, United Services Automobile Association raised its holdings in Assembly Biosciences by 1.1% during the fourth quarter. United Services Automobile Association now owns 51,764 shares of the biopharmaceutical company’s stock worth $1,171,000 after purchasing an additional 560 shares in the last quarter. 86.44% of the stock is currently owned by institutional investors and hedge funds.

Shares of ASMB stock traded up $0.18 during trading hours on Tuesday, reaching $13.38. The stock had a trading volume of 197,964 shares, compared to its average volume of 349,223. The stock has a fifty day simple moving average of $14.35. The company has a current ratio of 7.97, a quick ratio of 7.97 and a debt-to-equity ratio of 0.06. Assembly Biosciences has a 12 month low of $12.75 and a 12 month high of $44.65.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.01. The company had revenue of $3.89 million during the quarter, compared to analyst estimates of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. Sell-side analysts predict that Assembly Biosciences will post -4.34 EPS for the current year.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

See Also: What are the FAANG Stocks?

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.